Literature DB >> 28429426

Age-related health care disparities in multiple myeloma.

Mathieu Puyade1,2, Gautier Defossez1,2, François Guilhot1, Xavier Leleu1,3, Pierre Ingrand1,2.   

Abstract

Age is a well-known factor in solid tumours linked to lower adherence to guidelines. Scarce data exist for haematologic malignancies such as multiple myeloma (MM). The aim of the study was to investigate the relationships among age, adherence to guidelines in MM, and overall survival (OS).The Poitou-Charentes cancer registry has exhaustively registered incident cases of MM from 2008 to 2010. Diagnosis, staging, prognosis, and first-line treatment were compared to the international guidelines. Three hundred and sixty-seven patients aged 36 to 93 years were included. Compliance to diagnostic procedure was 98%, staging 62%, prognosis 30%, and first-line treatment 89%. Cytogenetic analysis was compliant in 37%. Younger age was the strongest factor associated with compliant provision of care (odds ratio 14.4 [6.1-33.8] for <66 years and 2.3 [0.9-6.1] for 66-74 years; P < .0001). The second independent factor was active versus smouldering myeloma (odds ratio 3.5 [1.6-7.3]; P = .0009). Adherence to guidelines is related with OS in multivariate analysis hazard ratio: 1.6 [1.0-2.5]; P = .03. Age is linked with inadequate provision of care in myeloma, particularly prognosis and first-line treatment. Compliance to guidelines seems to be related to OS taking into account the main prognostic factors. Future guidelines should stress the point that age and frailty need to be taken into account in myeloma care.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  age groups; guideline; health care disparities; multiple myeloma; overall survival

Mesh:

Year:  2017        PMID: 28429426     DOI: 10.1002/hon.2422

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

1.  Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.

Authors:  Liang Chen; Ke Yi; Hongyan Lan; Yajun Zhang; Simin Jin; Xiaoyu Mou; Hongming Xian; Weijun Fu; Rong Li
Journal:  Ann Transl Med       Date:  2022-06

2.  Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).

Authors:  Zoe McQuilten; Cameron Wellard; Elizabeth Moore; Bradley Augustson; Krystal Bergin; Hilary Blacklock; Simon Harrison; P Joy Ho; Tracy King; Hang Quach; Peter Mollee; Brian Rosengarten; Patricia Walker; Erica Wood; Andrew Spencer
Journal:  Br J Haematol       Date:  2022-07-11       Impact factor: 8.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.